Last Chance for Breakthrough Cancer Research Developments: 8th Annual Anti-Cancer Drug Discovery & Development Summit, July 17-18, 2006
Posted on: Monday, 10 July 2006, 09:01 CDT
BOSTON, July 10 /PRNewswire/ -- Many researchers believe the key to combating cancer in the 21st century will be through improved prevention, screening and early detection of the disease. And surely they are correct as when colon cancer is detected early, the cure rate is now 95 percent. Yet, cancer research is the building block of understanding and treating this wide-spread disease.
The 8th Annual Anti-Cancer Drug Discover & Development Summit, to be held on July 17-18, 2006, will include the most prominent experts in the field of cancer research as well as the latest anti-cancer research on: 1) Targeted Therapeutics, 2) Antibody Derived Targets & Biologics, and 3) Angiogenesis.
Highlighted research programs include the following: -- Targeting VEGF Pathway with mAb's and Small Molecules -- EGF Pathway Inhibitors (Erlotinib and Cetuximab) -- Emerging Approaches to Target the c-Met/ HGF Axis -- Selective and Multi-Targeted Kinase Inhibitors -- Novel Biologicals (CD20, CTLA4, Angiopoietins, PSCA, SDF and Eph) -- Emerging Data on Inhibitors of Mek, Hedgehog, CDK and HDAC
Complete list of participating companies and institutions includes: Agensys, Amgen, Arqule, Array Biopharma, Astrazeneca, Chemokine Therapeutics, Compound Therapeutics, Curagen, Curis, Dana-Farber Cancer Institute, Exelixis, Genentech, Genmab A/S, Harvard University, Hoffmann-La Roche, Immunogen, Ludwig Center for Cancer Research, MD Anderson Cancer Center, Medarex, Medimmune, MIT, OSI Pharmaceuticals, Pfizer, Sunesis, Sherris Pharma Partners, University of Texas and Whitehead Institute.
To receive the full agenda in PDF, to register, or for information on becoming a media partner, please contact Amy Yueh of Strategic Research Institute at ayueh@srinstitute.com or 212-967-0095, x258. The conference website is http://www.srinstitute.com/cancer .
Strategic Research Institute http://www.srinstitute.com/
Strategic Research Institute
CONTACT: Amy Yueh of Strategic Research Institute,ayueh@srinstitute.com, +1-212-967-0095, x258
Web site: http://www.srinstitute.com/http://www.srinstitute.com/cancer
Source: PRNewswire
Related Articles
- Ludwig Institute of Cancer Research Ltd., Brussels Branch, Issues Statement Concerning Prospect Therapeutics Inc's. GCS-100 Molecule
- 1.2 Million Dollars Recently Awarded to Institute for Myeloma and Bone Cancer Research
- Antisoma Announces Collaboration With The Institute of Cancer Research
- Antisoma and The Institute of Cancer Research to Collaborate on Novel Approach to Cancer Treatment
- Morphotek(R) Announces Collaborative Research Agreement With Ludwig Institute for Cancer Research
- Illumina Signs Fourth Genotyping Service Agreement With Leading UK-Based Cancer Research Group
- Onconova Therapeutics Announces Presentation of Clinical and Non-Clinical Results for Its Lead Compound ON 01910.Na at American Association of Cancer Research Conference in Los Angeles
- GSK Licenses Cancer Antigen Portfolio From Ludwig Institute for Cancer Research
- Publication in Cancer Research Shows Potential of Therapeutic Gene Silencing for a Broad Range of Diseases
- Abbott Northwestern's Virginia Piper Cancer Institute Joins the Pancreatic Cancer Research Team
 |
 |
User Comments (0)
RSS Feeds